Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Cut to “Underweight” at Barclays

Barclays downgraded shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) from an equal weight rating to an underweight rating in a research report report published on Monday morning, MarketBeat.com reports.

Several other equities analysts also recently weighed in on FMS. Sanford C. Bernstein lifted their price target on Fresenius Medical Care AG & Co. KGaA from $25.50 to $25.80 and gave the stock a “market perform” rating in a research report on Thursday, August 6th. Truist Financial dropped their price target on shares of Fresenius Medical Care AG & Co. KGaA from $25.00 to $24.00 and set a “hold” rating on the stock in a research note on Monday, October 12th. Weiss Ratings raised shares of Fresenius Medical Care AG & Co. KGaA from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. Zacks Research lowered shares of Fresenius Medical Care AG & Co. KGaA from a “hold” rating to a “strong sell” rating in a research note on Thursday, October 15th. Finally, Citigroup restated a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Friday, July 17th. Seven analysts have rated the stock with a Hold rating and five have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Reduce” and a consensus target price of $23.42.

Fresenius Medical Care AG & Co. KGaA Stock Performance

Fresenius Medical Care AG & Co. KGaA stock opened at $22.21 on Monday. The company has a quick ratio of 0.69, a current ratio of 0.99 and a debt-to-equity ratio of 0.37. The company has a market capitalization of $11.82 billion, a P/E ratio of 8.55, a PEG ratio of 5.33 and a beta of 0.78. The stock’s 50 day moving average is $22.32 and its 200 day moving average is $22.91. Fresenius Medical Care AG & Co. KGaA has a twelve month low of $20.02 and a twelve month high of $26.42.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported $0.64 earnings per share for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.01). The company had revenue of $5.59 billion for the quarter, compared to the consensus estimate of $5.52 billion. Fresenius Medical Care AG & Co. KGaA had a net margin of 4.23% and a return on equity of 9.08%. On average, equities research analysts predict that Fresenius Medical Care AG & Co. KGaA will post 2.23 earnings per share for the current fiscal year.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

A number of institutional investors and hedge funds have recently modified their holdings of FMS. Pzena Investment Management LLC raised its stake in shares of Fresenius Medical Care AG & Co. KGaA by 10.8% in the third quarter. Pzena Investment Management LLC now owns 16,617,575 shares of the company’s stock worth $371,901,000 after purchasing an additional 1,625,494 shares during the last quarter. Teachers Retirement System of The State of Kentucky boosted its position in shares of Fresenius Medical Care AG & Co. KGaA by 35.6% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 1,106,400 shares of the company’s stock valued at $24,761,000 after buying an additional 290,200 shares during the last quarter. Quantinno Capital Management LP increased its holdings in Fresenius Medical Care AG & Co. KGaA by 15.7% in the 1st quarter. Quantinno Capital Management LP now owns 341,343 shares of the company’s stock worth $7,701,000 after buying an additional 46,428 shares in the last quarter. Royal Bank of Canada increased its holdings in Fresenius Medical Care AG & Co. KGaA by 479.2% in the 1st quarter. Royal Bank of Canada now owns 216,861 shares of the company’s stock worth $4,893,000 after buying an additional 179,418 shares in the last quarter. Finally, Ritholtz Wealth Management increased its holdings in Fresenius Medical Care AG & Co. KGaA by 5.2% in the 3rd quarter. Ritholtz Wealth Management now owns 135,135 shares of the company’s stock worth $3,024,000 after buying an additional 6,732 shares in the last quarter. Institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co. KGaA is a healthcare company focused on treating people with chronic kidney failure. It provides dialysis care through a global network of treatment centers and supports patients who receive care in clinics or at home. The company also develops and supplies products used in dialysis, including dialysis machines, dialyzers, and related medical equipment and materials. Its services include clinical care and support for healthcare providers involved in kidney treatment.